Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

COVAXIN™ (BBV152) was recently awarded Emergency Use Listing by the World Health Organization Pediatric EUA submission based on immuno-bridging clinical trial in children, ages...

  • 1525285769828478976 Profile photo of Madelyn

    Covaxin has also been tested in a younger cohort of participants 2-18 years old in India. A Phase 2/3, open-label, multicenter study was conducted from May to July 2021, to evaluate the safety, reactogenicity, and immunogenicity of Covaxin in this group: https://t.co/Y0rgKpm9xc - view on twitter

Level of vaccine-induced spike and nucleoprotein antibodies titers demonstrated to be comparable to that following natural infection Immune memory against conserved nucleoprotein may provide...

MALVERN, Pa., March 04, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies...

COVAXIN™ (BBV152) was recently awarded Emergency Use Listing by the World Health Organization Pediatric EUA submission based on immuno-bridging clinical trial in children, ages...

  • 1484240586911596548 Profile photo of Madelyn

    FOR 2-4 YEAR OLDS: Covaxin has been pending at the FDA since November 5 and is a whole inactivated virion vaccine (more traditional design) which importantly allows host to see the whole virus giving T/B cells/antibodies across whole virus. https://t.co/Y0rgKpm9xc - view on twitter